Who are Fentanyl ev's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methadone Pill, Mylan generic fentanyl, Ketamine + methadone, Unrestricted Fentanyl, Normal dose of alfentanil hydrochloride, Methadone Maintenance Therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fentanyl-ev.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Fentanyl ev — Competitive Intelligence Brief

Fentanyl ev (Fentanyl ev) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic opioid agonist. Area: Pain management, Anesthesia.

marketed Synthetic opioid agonist Mu-opioid receptor (OPRM1) Pain management, Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Fentanyl ev (Fentanyl ev) — Azienda Sanitaria dell'Alto Adige. Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fentanyl ev TARGET	Fentanyl ev	Azienda Sanitaria dell'Alto Adige	marketed	Synthetic opioid agonist	Mu-opioid receptor (OPRM1)
Methadone Pill	Methadone Pill	Boston Medical Center	marketed	Synthetic opioid agonist	Mu opioid receptor (μ-OR)
Mylan generic fentanyl	Mylan generic fentanyl	University of Maryland, Baltimore	marketed	Synthetic opioid agonist	Mu-opioid receptor (OPRM1)
Ketamine + methadone	Ketamine + methadone	Cedars-Sinai Medical Center	marketed	NMDA receptor antagonist + synthetic opioid agonist combination	NMDA receptor (ketamine); mu opioid receptor (methadone)
Unrestricted Fentanyl	Unrestricted Fentanyl	Virginia Commonwealth University	marketed	Synthetic opioid agonist	Mu-opioid receptor (OPRM1)
Normal dose of alfentanil hydrochloride	Normal dose of alfentanil hydrochloride	University Hospital, Ghent	marketed	Synthetic opioid agonist	Mu opioid receptor (μ-OR)
Methadone Maintenance Therapy	Methadone Maintenance Therapy	Oregon Health and Science University	marketed	Synthetic opioid agonist	Mu opioid receptor (μ-opioid receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic opioid agonist class)

University of Maryland, Baltimore · 2 drugs in this class
Boston Medical Center · 1 drug in this class
L'Hospitalet de Llobregat · 1 drug in this class
Azienda Sanitaria dell'Alto Adige · 1 drug in this class
University Hospital, Ghent · 1 drug in this class
Virginia Commonwealth University · 1 drug in this class
Oregon Health and Science University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fentanyl ev — Competitive Intelligence Brief. https://druglandscape.com/ci/fentanyl-ev. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab